In accordance with previous studies, the AITL patients in our cohort were more likely to harbor mutations in genes of epigenetic modifiers and T-cell activation pathway (TET2 85%, RHOA 64% and IDH2 27%). The gene discussed is IDH2; the disease is angioimmunoblastic T-cell lymphoma.